News
-
-
PRESS RELEASE
Circus SE: 2025 Strategy Release Highlights Physical AI Leadership with Focus on CA-1
Circus SE unveils its 2025 strategy focusing on Physical AI leadership with CA-1 robot for labor-intensive industries, expanding beyond food service. CEO emphasizes transformative potential and global growth opportunities -
-
-
PRESS RELEASE
Assessing Post-Cardiac Surgery Kidney Recovery Through PenKid's Emerging Role in Renal Replacement Therapy Decisions
SphingoTec GmbH announces groundbreaking research on using penKid biomarker to assess kidney recovery in post-cardiac surgery patients undergoing CRRT. Study reveals promising outcomes for CRRT liberation decisions -
PRESS RELEASE
Original-Research: MAX Automation SE (von NuWays AG): BUY
Research update: Mixed FY25e outlook for MAX Automation SE with target price of EUR 7.00. Sales decline expected due to low order backlog, while bdtronic faces challenges from EV crisis. Elwema shows resilience with steady orders -
-
-
PRESS RELEASE
Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)
Biotest AG reaches a significant milestone by submitting a Biologics License Application for Fibrinogen to the US FDA, aiming to address fibrinogen deficiency -
PRESS RELEASE
ENCAVIS: Delisting of ENCAVIS AG shares from Hamburg Stock Exchange takes effect at the end of 31 January 2025
ENCAVIS AG shares to be delisted from Hamburg Stock Exchange by end of January 2025. Company applied for Frankfurt Stock Exchange as well. Encavis operates renewable energy plants across Europe with a total saving of around 0.8 million tonnes of CO2 per year. Encavis is a member of the UN Global Compact and UN PRI network
